drugset / Trial / NCT00374543

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

NCT00374543

Phase 4 Terminated 3 enrolled Massachusetts General Hospital Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study proposes to examine the potential safety and efficacy of ziprasidone for patients with anxiety and bipolar disorder on anxiety outcomes, bipolar symptoms, and on measures of quality of life and resilience.

Timeline

Start
2006-02
Primary completion
2007-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg
Subject Ziprasidone Small molecule 160 mg